Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"National Health Service (NHS)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Successful Eloctaq Bid Should Widen Access to the Drug in the UK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOBI's Kineret\u00ae (anakinra) Approved in Russia for the Treatment of CAPS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi to Present Data at the ISTH 2021 Within Rare Haematology Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Agnafit Bidco","pharmaFlowCategory":"D","amount":"$8,000.0 million","upfrontCash":"$8,000.0 million","newsHeadline":"Statement by The Board of Directors of Swedish Orphan Biovitrum AB in Relation to The Public Cash Offer by Advent and GIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Swedish Orphan Biovitrum AB"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Swedish Orphan Biovitrum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Statement by The Board of Directors of Swedish Orphan Biovitrum AB in Relation to The Public Cash Offer by Advent and GIC

Details:

Elocta®/Eloctate® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for the treatment of haemophilia A using Fc fusion technology to prolong circulation of factor VIII in the body.

Lead Product(s): Efmoroctocog Alfa

Therapeutic Area: Genetic Disease Product Name: Elocta

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Agnafit Bidco

Deal Size: $8,000.0 million Upfront Cash: $8,000.0 million

Deal Type: Acquisition September 02, 2021

ASK
US

Upload
your Pipeline Activity

Swedish Orphan Biovitrum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sobi to Present Data at the ISTH 2021 Within Rare Haematology Diseases

Details:

Alprolix® (eftrenonacog alfa), is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body.

Lead Product(s): Eftrenonacog Alfa

Therapeutic Area: Genetic Disease Product Name: Alprolix

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2021

ASK
US

Upload
your Pipeline Activity

Swedish Orphan Biovitrum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SOBI's Kineret® (anakinra) Approved in Russia for the Treatment of CAPS

Details:

Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.

Lead Product(s): Anakinra

Therapeutic Area: Genetic Disease Product Name: Kineret

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2021

ASK
US

Upload
your Pipeline Activity

Swedish Orphan Biovitrum AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Successful Eloctaq Bid Should Widen Access to the Drug in the UK

Details:

The National Health Service (NHS) and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Elocta (efmoroctocog alfa), by lifting prior volume restrictions for the drug.

Lead Product(s): Efmoroctocog alfa

Therapeutic Area: Genetic Disease Product Name: Elocta

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: National Health Service (NHS)

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 29, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY